Atea Pharmaceuticals (AVIR) Operating Leases (2022 - 2025)

Atea Pharmaceuticals' Operating Leases history runs 4 years deep, the most recent figure standing at $213000.0 for Q3 2025.

• In Q3 2025, Operating Leases fell 79.62% year-over-year to $213000.0; the TTM figure through Sep 2025 stood at $213000.0 (down 79.62% YoY), while the FY2024 annual figure was $842000.0, down 48.72% from the prior year.
• Operating Leases for Q3 2025 stood at $213000.0, down from $425000.0 in the prior quarter.
• The five-year high for Operating Leases was $2.8 million in Q2 2022, with the low at $213000.0 in Q3 2025.
• The 4-year median for Operating Leases is $1.6 million (2023), against an average of $1.6 million.
• The sharpest annual moves came in 2023 and 2025: Operating Leases decreased 19.83% in 2023, then slumped 79.62% in 2025.
• Atea Pharmaceuticals' Operating Leases stood at $2.4 million in 2022, then slumped by 31.67% to $1.6 million in 2023, then tumbled by 48.72% to $842000.0 in 2024, then slumped by 74.7% to $213000.0 in 2025.
• Business Quant data shows AVIR's Operating Leases at $213000.0 in Q3 2025, $425000.0 in Q2 2025, and $634000.0 in Q1 2025.